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Abstract
Background: Tissue-specific expression of CYP450s can regulate the intracellular concentration of drugs and explain inter-
subject variability in drug action. The overall objective of our study was to determine in a large cohort of samples, mRNA
levels and CYP450 activity expressed in the human heart.
Methodology: CYP450 mRNA levels were determined by RTPCR in left ventricular samples (n=68) of explanted hearts from
patients with end-stage heart failure. Samples were obtained from ischemic and non-ischemic hearts. In some instances
(n=7), samples were available from both the left and right ventricles. A technique for the preparation of microsomes from
human heart tissue was developed and CYP450-dependent activity was determined using verapamil enantiomers as probe-
drug substrates.
Principal Findings: Our results show that CYP2J2 mRNA was the most abundant isoform in all human heart left ventricular
samples tested. Other CYP450 mRNAs of importance were CYP4A11, CYP2E1, CYP1A1 and CYP2C8 mRNAs while CYP2B6
and CYP2C9 mRNAs were present at low levels in only some of the hearts analyzed. CYP450 mRNAs did not differ between
ischemic and non-ischemic hearts and appeared to be present at similar levels in the left and right ventricles. Incubation of
verapamil with heart microsomes led to the formation of nine CYP450-dependent metabolites: a major finding was the
observation that stereoselectivity was reversed compared to human liver microsomes, in which the R-enantiomer is
metabolized to a greater extent.
Conclusions: This study determined cardiac mRNA levels of various CYP450 isozymes involved in drug metabolism and
demonstrated the prevalent expression of CYP2J2 mRNA. It revealed that cardiomyocytes can efficiently metabolize drugs
and that cardiac CYP450s are highly relevant with regard to clearance of drugs in the heart. Our results support the claim
that drug metabolism in the vicinity of a drug effector site can modulate drug effects.
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Introduction
The cytochrome P450 (CYP450) is a superfamily of hemopro-
teins that are the terminal oxidases of the mixed function oxidase
system involved in the biotransformation of endogenous com-
pounds and xenobiotics.[1] To date, 57 genes and 58 pseudogenes
of the CYP450 superfamily have been characterized from the
human genome. (http://drnelson.utmem.edu/CytochromeP450.
htlm) This superfamily is composed of 18 families of genes, four of
which—CYP1, CYP2, CYP3 and CYP4—are involved in the
metabolism of clinically used drugs.
Although CYP450 enzymes are mainly expressed in the liver,
most extrahepatic tissues express CYP450 isozymes to varying
degrees. The heart is no exception. Indeed, recent reports have
demonstrated the presence of CYP450 gene products in a
cardiomyoblast cell line [2], in cultured rat cardiomyocytes [3],
in the heart of several animal species such as rat [4,5], rabbit [6],
fish [7], sheep [8] and pig [9] and more importantly, in samples of
a few explanted human hearts [10,11,12]. However, only a
handful of studies have reported data on the relative expression of
CYP450s from the CYP1-4 families in human heart tissues. When
information is available, it is based on a small number (often ,10)
of explanted hearts from subjects with various conditions.[10,
11,12,13] For instance, Thum and Borlak report the presence of
CYP1A1, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP4B1
mRNAs in seven explanted hearts. No mRNA for CYP3As could
be detected in these samples.[10]
The functional role of CYP450s in cardiovascular health and
disease has gained great interest in the scientific communi-
ty.[14,15] For example, several studies have shown the role of
CYP450s expressed in cardiovascular tissues for the catabolism of
endogenous compounds such as arachidonic acid and ste-
roids.[16,17] Arachidonic acid is transformed into epoxyeicosa-
trenoic acid metabolites (EETs) that regulate vascular tone and
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CYP450-mediated formation of estradiol and hydroxyestradiol is
associated with a decrease in cardiomyocyte apoptosis and a
protective role against cardiac hypertrophy.[19,20] Furthermore,
testosterone metabolism appeared to be increased in hypertro-
phied hearts due to the induction of CYP450s leading to increased
levels of lipid peroxidation.[21]
Attention has been paid to the role of CYP2Cs in cardiovascular
homeostasis. In particular, CYP2C9 may play a role in the onset
and progression of cardiovascular diseases and in inflammatory
processes since this isozyme can produce vasoreactive EETs and
generate reactive oxygen species. Inhibition of CYP2C9 activity
increased post-ischemic endothelium-dependant vasodilatation
and reduced post-ischemic vascular superoxide production.[22]
The infarct size was reduced and post-ischemic coronary flow was
increased in rat hearts.[23] Fischer et al. report that flow-mediated
dilation in human conductance arteries is reduced after infusion of
sulfaphenazole, a CYP2C9 inhibitor, supporting the idea that
CYP2C-dependent metabolites play a role in endothelium-
mediated vasodilation.[24] They also observe that CYP-depen-
dent flow-mediated dilation is preserved in patients with heart
failure.[24] A relationship between CYP2J2, endogenous gener-
ation of EETs and cardioprotective effects has also been reported.
Increased expression of CYP2J2 in mice hearts decreases
ischemia-reperfusion damage through production of EETs which
affect the KATP channel activity and MAP kinase signalling.[25]
Several drugs exert their pharmacological effects on the heart
and are prone to being metabolized by CYP450 isozymes
expressed in cardiac tissues. The cellular concentration of drugs
within the heart may therefore be modulated by the intrinsic
activity of CYP450 isozymes found in cardiac tissues. To date,
little is known about the magnitude of drug metabolism occurring
in the human heart and no information is available concerning
site-specific drug-drug interactions as they pertain specifically to
the heart.
In this light, the objectives of our study were: 1) to determine the
relative levels of CYP450 mRNAs (CYP1, CYP2, CYP3 and
CYP4 families) in a large cohort (n=68) of explanted left
ventricular heart samples from patients with end-stage heart
failure undergoing cardiac transplant; 2) to compare the relative
CYP1-4 mRNA levels in samples from ischemic and non-ischemic
hearts; 3) to compare the relative CYP1-4 mRNA levels in left and
right ventricular tissues in selected subjects (n=7); 4) to
demonstrate by immunohistochemical studies the presence of
some CYP450s in human cardiac myocytes; 5) to develop
procedures for the preparation of microsomes from human heart
tissue; 6) to establish the CYP450-dependent activity of micro-
somes prepared from human heart ventricles using verapamil as a
probe-substrate; and 7) to characterize the enantioselective
metabolism of R- and S-verapamil in human heart microsomes.
Verapamil was used as a probe-drug since it is known to be
metabolized by several CYP450 isozymes, it possesses cardiovas-
cular actions for which variability in CYP450 activities may be
relevant. and finally, Walles et al. reported the formation of
various verapamil metabolites in human heart samples in a pilot
study.[26]
Results
CYP450 mRNA levels in human hearts
The demographic data and characteristics of patients and
subjects from which samples were collected are summarised in
Table 1. Our cohort was composed of 75 different heart samples,
including 68 samples from the left ventricles of all subjects
included in this study and 7 additional samples from the right
ventricles of a subgroup of patients. All results presented in this
section are expressed relative to the housekeeping gene GAPDH,
uniformly expressed in all tissues analyzed.
Relative CYP450 mRNA levels of measured in human
hearts. Figure 1 illustrates mRNA levels of CYP450s of interest
measured in the entire cohort of hearts studied. CYP2J2 mRNA
levels largely exceeded (,3 million to 62 times) those determined
on average for other isozymes (p,0.008). CYP4A11, CYP2E1,
CYP1A1 and CYP2C8 mRNAs were present at an intermediate
level while CYP2B6 and CYP2C9 mRNAs were present at very
low levels in some of the analyzed hearts.
Comparison of the relative CYP450 mRNA levels in
ischemic and non-ischemic samples. We compared
CYP450 mRNA levels in ischemic (n=24) and non-ischemic
(n=40) hearts from patients with end-stage heart failure. Figure 2
indicates that expression levels were unaffected by ischemic status.
However, CYP2C9 mRNA levels tended to be higher in
ventricular samples from ischemic hearts than from non-
ischemic ventricles.
Comparison of the relative cardiac CYP450 mRNA levels
between male and female patients. No differences in mRNA
levels were observed between males and females except for
CYP2J2, for which mRNA levels were lower in men compared to
women (1.560.8 vs. 2.260.8; p,0.01).
Comparison of the relative cardiac CYP450 mRNAs
between left and right ventricular samples. Samples were
obtained from a limited number of subjects (n=7) from both their
left and right ventricles, thereby making it possible to compare
these two tissue sites (Figure 3). Overall, no major differences were
observed in the relative expression of CYP450s except for
CYP2E1, for which higher levels tended to be observed in the
right ventricles (1.060.5 vs. 0.660.3; p=0.05).
Detection of CYP450 proteins in human cardiac myocytes
Immunohistochemical studies were performed to confirm
CYP450 expression in human cardiomyocytes. Primary antibody
negative controls and CYP450 antibody positive staining results
clearly indicated that CYP2J2 and CYP2Cs proteins were
expressed in human cardiomyocytes (Figure 4). It should be noted
that our immunohistochemical studies included a control for
potential false positive results with lipofuscine.
CYP450 activities in human heart microsomes
The method described here was developed and validated for the
preparation of human heart microsomes that retain metabolic
activities. More than 40 combinations of buffer, co-factors and
Table 1. Characteristics of patients from whom samples were
obtained.
Demographic data
Gender (male:female)* 41:23
Weight (kg)* 73619
Height (cm)* 17069
Number of left ventricle samples
Number of right ventricle samples
68
7
Number of ischemic vs. non-ischemic hearts
* 24:40
*data are missing for 4 patients.
Mean 6S.D.
doi:10.1371/journal.pone.0015666.t001
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buffer at a range of pH values, sucrose, glucose, glycerol,
detergents (CHAPS, TRITION), and CompleteH. The optimal
mixture based on maximal metabolic activity was obtained with a
phosphate buffer containing potassium chloride, PMSF and DTT
combined with sonication procedures as described in the Methods
section.
Verapamil metabolism in human heart microsomes.
Incubations were performed using the probe-drug substrate
verapamil. Figure 5 shows that 9 verapamil metabolites could be
detected and 4 metabolites quantified following 4-hour incubations
with human heart microsomes prepared according to our procedure.
We demonstrated that the formation of verapamil metabolites was
time-dependent and linearity maintained for the 4-hour incubation
period. The formation rate of verapamil metabolites was
concentration dependent (50, 100 and 400 mM of verapamil): the
amount of metabolites formed increased 2-4 fold in this range of
concentrations. Verapamil metabolism was completely eliminated in
the absence of a functional NADPH regenerating-system (Figure 5),
thereby confirming that metabolite formation was not due to
chemical degradation of the substrate. As well, metabolite
formation was almost completely eliminated in incubations with
CO or nitrogen gas.
The effects of chemical inhibitors on the metabolism of
verapamil were studied using metyrapone, N-octylamine, SKF-
525 and methimazole. Results of these studies are presented in
Figure 6. When potent CYP450 inhibitors (metyrapone, N-
octylamine or SKF525) were added to the incubation mixture, the
formation of all major verapamil metabolites decreased signifi-
cantly (more than 80%). In contrast, methimazole (a strong
inhibitor of flavoprotein monooxygenase (FMO) enzymatic
system) only slightly decreased the formation of verapamil
metabolites. To further discriminate between the contribution of
FMOs and CYP450s, the metabolism of verapamil was evaluated
with human heart microsomes previously heated at 60uC for 10
minutes. This procedure is known to eliminate CYP450 activity
while not affecting FMOs. Results showed that pre-treatment of
human heart microsomes by heating blunted metabolic activity
(Figure 5). These results support the claim that the CYP450
enzymatic system contributes to the metabolism of verapamil in
human heart microsomes.
Additional experiments were performed with selective chemical
inhibitors for various CYP450 isozymes. A significant decrease
(30–90%) was observed in the formation of various metabolites
following incubation of verapamil with sulfaphenazole (10 mM), a
CYP2C inhibitor, or ketoconazole (1 mM), a compound known to
inhibit CYP3As and CYP2J2. In contrast, no significant inhibition
was observed even with high concentrations (5 mM) of quinidine
(CYP2D6 inhibitor) (Figure 6).
Inter-subject variability in CYP450 activities from human
heart microsomes. A wide variability in the profile of
verapamil metabolism was observed among microsomes
prepared from various human heart samples (n=20). Median
values for the formation rate of verapamil metabolites produced by
left ventricular microsomes (range; minimum-maximum values)
were 27 (2.1–76), 21 (3.2–108), 25 (5.8–214) and 12 (3.2–81)
pmol/min/mg of heart microsomal proteins for PR22, D702,
norverapamil and the hydroxymetabolite, respectively. In
microsomes prepared from right ventricles (n=8), median values
were 21 (3.7–64.4), 21 (3.2–74), 39 (5.8–145) and 16 (3.0–48)
pmol/min/mg of heart microsomal proteins for PR22, D702,
norverapamil and the hydroxymetabolite, respectively. Figure 7
Figure 1. CYP450s mRNA levels in failing human hearts. Relative levels of CYP450 mRNAs measured in samples from human left ventricles.
Levels were determined and compared using the 2
2DCT method without a calibrator.
doi:10.1371/journal.pone.0015666.g001
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which microsomes were prepared from both left and right
ventricles. Data obtained suggest that both tissues display similar
activity levels (p.0.4).
Enantioselective metabolism. We performed incubations
with human heart microsomes using either R-verapamil or S-
verapamil as substrates. In all human heart microsomes tested
(n=7) and for all metabolites, the formation rates measured for
Figure 2. CYP450 mRNA levels in ischemic and non-ischemic heart samples. Comparison of the relative levels of CYP450 mRNAs in samples
from hearts with a diagnosed ischemic status (n=25) or non-ischemic status (n=41). No major differences were observed in the relative expression of
CYP450 mRNAs under these conditions. Levels were determined and compared using the 2
2DDCT method with a calibrator.
doi:10.1371/journal.pone.0015666.g002
Figure 3. CYP450 mRNA levels in left and right ventricular heart samples. Comparison of the relative levels of CYP450 mRNAs in samples
from paired left and right ventricles (n=7). No major differences were observed in the relative expression of CYP450s in the left and right ventricular
tissues except for CYP2E1 mRNAs, where higher levels tended to be observed for the right ventricle (1.060.5 vs 0.660.3; p=0.05). Levels were
determined and compared using the 2
2DDCT method with a calibrator. mRNA from CYP2C9 was detected in one heart (data not shown). RV: right
ventricle; LV: left ventricle.
doi:10.1371/journal.pone.0015666.g003
CYP450 Activity and mRNA Levels in Human Hearts
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the S-enantiomer (Figure 8).
Discussion
Results obtained in this study are derived from the largest
cohort of human heart samples (n=75) ever analyzed for
determining the relative mRNA levels for CYP450 isozymes
involved in drug-metabolism. We confirmed that CYP2J2 mRNAs
were the most abundant in the left and right ventricles of human
hearts with an increased expression in females compared to males.
Our results also indicated that CYP450 mRNA levels were not
affected by ischemic or non-ischemic conditions in patients with
end-stage heart failure and suggested that CYP450 mRNAs were
present at similar levels in both the left and right ventricles. Lastly,
we noticed that CYP2C9 was detected in less than 10% of human
hearts. We also determined CYP450 activity in human heart
microsomes using verapamil as a probe-drug substrate by showing
the formation of nine metabolites. In contrast to the stereoselec-
tivity observed in the liver for the metabolism of verapamil
preferred metabolism of the R-enantiomer was demonstrated. It
should be noted that our results were obtained with hearts from
patients with end-stage heart failure and that had previously been
exposed to many drugs.
Using immunoblotting techniques, Zeldin’s group reported in
1996 that CYP2J2 was highly expressed in human heart
tissues.[11] Their study was followed by Thum and Borlak’s study
using RT-PCR, which suggested that several CYP450s were
expressed in the human heart.[10] Drawing on data obtained from
7 explanted hearts from heart failure patients and 2 hearts from
normal subjects, they reported that the presence of CYP1A1,
CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP4B1 mRNAs.
No mRNA for CYP3A4, CYP3A5 or CYP3A7 could be
detected.[10] Using a semi-quantitative assay and a pool of
human heart samples (n=3), they further demonstrated that gene
expression for CYP2J2 and CYP1A1 was the most abundant.[26]
They confirmed these results in 11 diseased and 2 normal human
hearts, showing that CYP450 gene expression in the left ventricle
was limited to CYP1A1, CYP2A6, CYP2B6, CYP2C8, CYP2E1,
CYP2J2 and CYP4A11.[21] Recent studies conducted with
quantitative real-time PCR and samples from 8 explanted human
hearts indicated that CYP2J2 mRNA values were .900 times
Figure 4. CYP2C and CYP2J2 immunohistochemical staining in human hearts. Immunohistochemical staining of human heart samples. The
presence of CYP2Cs (upper panel) and CYP2J2 (lower panel) was revealed by dark elements inside the cardiomyocytes, which are absent in negative
controls (inserts).
doi:10.1371/journal.pone.0015666.g004
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results, obtained in a large cohort of human hearts, support data
from these pilot studies and confirm high CYP2J2 mRNA levels in
human hearts. Furthermore, our access to a large number of
human hearts enabled us to demonstrate high inter-subject
variability, especially for CYP2J2 and CYP1A1 mRNA levels.
It is noteworthy that CYP2C9 and CYP2B6 mRNAs were only
detected in a small number of hearts. However, CYP2C9 mRNA
levels tended to be greater in samples from ischemic hearts. This
result supports data obtained in rats indicating that chronic
hypoxia led to an increase in rat CYP2C9 expression in mesenteric
arteries.[27] It has also been reported that hypoxia increases the
expression of CYP2C mRNAs and proteins and enhanced 11,12-
EET production in human endothelial cells.[28] The fact that
CYP2C9 mRNA was detected in only 10% of our samples and
increased in ischemic hearts may suggest that a certain amount of
this mRNA originates from endothelial cells in some but not in
other ventricular samples.
We observed that CYP2J2 mRNA levels were higher in female
than in male left ventricular samples. One could suggest that the
sex-dependant CYP2J2 mRNA expression explains higher sus-
ceptibility of men for the onset or progression of cardiovascular
diseases. This hypothesis needs to be investigated and confirmed
by other studies. Gender-differences in the expression of CYP450s
isozymes are also an interesting observation. Earlier studies have
reported that CYP3A4 expression (mRNA and protein levels) is
sex-dependant expression, with higher activity measured in
women.[29,30,31]
Thum and Borlak’s group suggest that CYP450 mRNAs are
predominantly expressed in the right ventricle.[10] In contrast,
our results clearly show the presence of CYP450 mRNAs in the
left ventricles. The only exception could be for CYP2E1. A similar
extent of metabolism measured in the formation of verapamil
metabolites from both the left and right ventricles further confirms
our observations.
Results obtained by immunohistochemistry analyses demon-
strate that CYP450 proteins such as CYP2J2 and CYP2Cs are
expressed in human cardiomyocytes. These results are in line with
observations by DeLoziers et al., although they did not control for
false positive results due to lipofuscine.[12] In our study, the
presence of CYP450 proteins was clearly demonstrated inside
cardiomyocytes away from nucleus and detritus residues of
proteins accumulated by lipofuscine.
Our final series of experiments aimed at demonstrating CYP450
activities in microsomes prepared from human heart samples. This
objective required the development and validation of standardized
procedures for the reproducible preparation of microsomes that
retain activity. After several attempts, microsomes from 20 human
heart samples were prepared and used to characterize the
metabolism of the probe-drug verapamil. Nine metabolites were
detected following incubations with verapamil. We demonstrated
that the formation of these metabolites was CYP450 dependent
and unrelated to FMO activity. We also demonstrated that left
and right ventricles possess similar CYP450 activity levels.
Inconsistent results had been previously reported in small studies
for verapamil and testosterone.[10,21,26] Our study is the first to
Figure 5. Verapamil and its metabolites produced following incubation with human heart microsomes. HPLC chromatogram depicting
nine metabolites detected following the incubation of verapamil with microsomes prepared from human heart ventricles. Structure allocation was
established following peak collection and reanalysis by LC-MSMS according to Walles et al. assay.[26] Metabolites PR22, D702, norverapamil and a
hydroxymetabolite (retention time 14 min) were present in sufficient amounts to allow quantification. The characterization of CYP450-dependency
on the formation of four major verapamil metabolites by microsomes prepared from human heart samples is illustrated. Metabolites could not be
detected in the absence of a NAPDH regenerating system or in the presence of pre-heated microsomes.
doi:10.1371/journal.pone.0015666.g005
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metabolism of drug in human cardiac tissue.
Verapamil is a calcium channel blocking agent commonly
prescribed in the treatment of angina pectoris, coronary artery
disease, cardiac arrhythmias and hypertension. Verapamil under-
goes extensive hepatic first-pass metabolism; O-demethylation, N-
demethylation and N-dealkylation are the major verapamil
metabolism pathways. Previous studies have shown that CYP3A4,
CYP3A5, CYP2C8 and, to a much lesser extent, CYP2E1 and
CYP1A2 are involved in the metabolism of verapa-
mil.[32,33,34,35] Verapamil is used clinically as a racemic mixture
of S- and R-enantiomers having various pharmacokinetic and
pharmacological properties. Following oral administration, the S-
enantiomer is preferentially metabolized upon first-pass metabo-
Figure 6. Effects of CYP450 chemical inhibitors. Inhibition of the formation of the four major verapamil metabolites by chemical inhibitors of
CYP450s. Significant inhibition in the formation of most metabolites was observed with potent CYP450 inhibitors (SKF525, n-octylamine, metyrapone)
while slight inhibition was observed with the FMO inhibitor methimazole.
doi:10.1371/journal.pone.0015666.g006
Figure 7. Metabolism of verapamil in right versus left
ventricles. Comparison of the formation of four major verapamil
metabolites by microsomes prepared from left and right paired
ventricles of human heart samples (n=8).
doi:10.1371/journal.pone.0015666.g007
Figure 8. Stereoselectvity of verapamil metabolism in human
hearts. Stereoselective metabolism in the formation of the four major
verapamil metabolites by microsomes from human heart ventricles
(n=7).
doi:10.1371/journal.pone.0015666.g008
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enantiomer.[36] The S-enantiomer is also the eutomer for calcium
channel blocking.[37] We report for the first time on the
stereoselective metabolism of verapamil by human heart micro-
somes. The same metabolism pattern (i.e., the same metabolites
appeared to be formed) was observed for both verapamil
enantiomers. However, the formation rates of all metabolites were
higher for R-verapamil than for the S-enantiomer (p,0.02). This
finding underlines the importance of studying CYP450 activity in
tissues expressing the effector protein to gain a better understand-
ing of drug action.
In conclusion, we performed a thorough determination of
CYP450 mRNA levels using the largest cohort of human hearts
ever analysed. This study pertains to the role of cardiac CYP450s
in cardiac-specific drug metabolism and, by extension, to cardiac
pathophysiology. To date, little is known about site-specific drug-
drug interactions as they relate specifically to the heart. In
particular, while liver microsomes express low levels of CYP2J2
and are therefore not taken into account in routine drug-drug
interaction screening, CYP2J2 is highly expressed in the heart and
could be extremely relevant for the local clearance of drugs and
metabolite formation in the heart.
Materials and Methods
Approval for the use of human tissue materials was obtained
from the Ethics Review Board at the Montreal Heart Institute and
fully complied with procedures from the Re ´seau d’E ´change de
Tissus et E ´chantillons Biologiques du Que ´bec (RETEB). Written
consent was obtained from all patients from whom tissues were
obtained.
Preparation of samples
Heart samples were obtained from patients suffering from end-
stage heart failure and undergoing heart transplant. Immediately
after explantation, the hearts were immersed in a cold transplan-
tation buffer, rapidly mounted on an extracorporal circulating
pump and perfused for 10 minutes with the same buffer. Left and
right ventricular samples (4–10 g) were prepared from the apex
region outside of apparent ischemic scars and immediately frozen
in liquid nitrogen. RNA was isolated and microsomes prepared in
thawed samples after removal of fat, fibrous tissue, and large
vessels apparent in the samples.
CYP450 mRNA levels in human hearts
Isolation of RNA and preparation of cDNA. Total RNA
was extracted from 68 human explanted hearts from patients with
end-stage heart failure (n=68). About 50 mg of left ventricular
tissue was homogenized in 1 mL of Trizol and transferred to a
2 mL tube. Seven paired samples available from the right
ventricles of patients were processed in the same way.
Chloroform (200 mL) was added, the mixture shaken for 15
seconds, and then centrifuged at 12,000 g for 15 minutes. The
upper aqueous layer was transferred to a new tube and ethanol
70% was added (1:1 volume). RNA was extracted using the
Qiagen kit (RNeasy Mini kit; Qiagen Sciences, MD, USA)
according to the manufacturer’s recommendations. RNA quality
was assessed by determining the variability of CT values of
GAPDH since this marker as been identified as a valid
housekeeping gene in heart tissues. Total RNA (1 mg) from
each sample was used for reverse transcription. RNA, random
primers (3 mg) and dNTP (25 mM) were preheated for 5 minutes
at 65uC, then 5X-first strand buffer, 40 units of RNAse inhibitor,
DTT (0.01M) and 200 units of Superscript II (Invitrogen,
Carlsband, CA, USA) and diethylpyrocarbonate-treated water
were added to a final volume of 20 mL. Reverse transcription was
carried out for 50 minutes at 42uC and stopped by heating to
70uC for 15 minutes. The resulting cDNA was frozen at 220uC
until analyzed.
Real-time PCR analysis. Quantitative real-time PCR was
performed using TaqMan probe and primer sets from Applied
Biosystem (Foster, CA, USA). The assay IDs were: CYP1A1
(Hs00153120_m1), CYP2B6 (Hs0059368_m1), CYP2C8 (Hs00-
946140_g1), CYP2C9 (Hs00426397_m1), CYP2E1 (Hs00593-
68_m1), CYP2J2 (Hs00356035_m1), CYP4A11 (Hs001679-
61_m1) and GAPDH (Hu_GAPDH). cDNA was diluted 20-fold
(10 ng/reaction), mixed with TaqMan PCR Master Mix and
amplified using cycling conditions for 50 cycles. Reactions were
run in a RotorGene Detector model 6000 (Corbett Research,
Mortlake, Australia).
Comparison of the relative mRNA expression of various
CYP450s was performed using the DCT method (CTCYP450-
CTGAPDH) to ascertain relative levels of isoenzymes among them.
Data were expressed as the ratio of the target mRNA to GAPDH
mRNA (2
2DCT).[38,39] For their part, mRNA levels associated
with the expression of each isozyme within a specific condition
(ischemic vs. non-ischemic heart samples, male vs. female and left
vs. right ventricles) were determined using a calibrator and the
2
2DDCT method.[38] Determination of mRNA levels was
performed in triplicate for each gene, and two independent
experiments were repeated to confirm results.
Detection of CYP450 proteins in human cardiomyocytes
by immunohistochemistry
Immunohistochemical detection was performed on human
frozen tissues using a Discovery XT system (Ventana Medical
Systems, Tucson, AZ). After antigen retrieval with proprietary
reagents, primary antibodies anti-CYP2J2 (sc-66364) and an anti-
Cytochrome P450 clone 2C8+2C9+2C19+2C12 (ab22596) were
applied. Goat anti-human CYP2J2 (Santa Cruz Biotechnology,
Inc., CA) was incubated for 2 hours at room temperature. Rabbit
anti-human Cytochrome P450 clone 2C8+2C9+2C19+2C12
(Abcam Inc, Cambridge, MA) was incubated for 60 minutes at
room temperature. Sections were then incubated with a
secondary biotinylated anti-goat or anti-rabbit antibody (Jackson
ImmunoResearch). Streptavidin horseradish peroxidase and 3,39-
diaminobenzidine were used according to the manufacturer’s
instructions (Ventana Medical Systems). Lastly, sections were
counterstained with hematoxylin and analyzed by standard light
microscopy.
CYP450 activities in human heart microsomes
Materials. Verapamil, S-verapamil, R-verapamil and
norverapamil were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Metyrapone, methimazole, SKF525A, N-octylamine
and cofactors (NADP+, D-glucose 6-phosphate and glucose 6-
phosphate dehydrogenase) were also obtained from Sigma-Aldrich
(St. Louis, MO, USA). EDTA was purchased from JT Baker
(Phillipsburg, NJ, USA). Other chemicals used were of the highest
quality commercially available.
HPLC analysis. The HPLC system (Thermo Separation
products, Fremont, CA) consisted of a SpectraSystem P4000
pump, a SpectraSystem AS3000 autosampler, a FL3000 fluo-
rescence detector, a SpectraSystem UV3000 ultraviolet detector
and PC1000 System Software. Quantification of verapamil and
major verapamil metabolites was performed after slight adjustments
to the assay described by Wang et al.[40] Briefly, separation of
verapamil metabolites was achieved on a phenyl-hexyl column
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mobile phase containing a potassium phosphate buffer (10 mM,
pH 7.0), acetonitrile, methanol and trietylamine (40:38:22:0.1).
Eluent was monitored by fluorescence absorbance at l=204 and
314 nm (absorption and emission wavelengths, respectively).
Intraday and interday coefficients of variation were less than 5%
and 10%, respectively.
Preparation of human heart microsomes. Frozen samples
of human heart ventricles (4–10 g) were immersed in cold
phosphate buffer 100 mM (pH 7.4) containing potassium
chloride 150 mM, EDTA 1 mM, dithiotreitol 0.5 mM and
PMSF 0.01 mM (1:3, w/v). Tissue was roughly sliced prior to
homogenization using a Polytron. The resulting suspension was
sonicated 3 times for 5–10 seconds. Homogenization and
sonication were performed on ice. Microsomal fractions were
isolated by centrifugation at 10,000 g for 20 minutes. The
resulting supernatant was centrifuged twice at 100,000 g for 2
consecutive 90-minute periods. The final microsomal pellet was
resuspended in a phosphate buffer 100 mM (pH 7.4), potassium
chloride 150 mM and EDTA 1 mM. All procedures were
performed at 4uC. Incubations with verapamil were performed
on freshly isolated microsomes. The leftover heart microsomes
were immediately shock frozen in liquid nitrogen for subsequent
protein quantification. Microsomal heart proteins were quantified
using a BCA Pierce kit.
In vitro incubations. All microsomal incubations were
performed in duplicate. The standard incubation mixture (final
volume, 500 mL) consisted of microsomes (200 mL), 195 mL
phosphate buffer 50 mM (pH 7.4), 100 mL NADPH-
regenerating system solution and 5 mL substrate (verapamil 50,
100 or 400 mM). The NADPH-regenerating solution contained
NADP
+ (498 mg), D-glucose 6-phosphate (502 mg), MgCl2 5m M
and 0.2 U glucose 6-phosphate dehydrogenase.
Incubations containing microsomes, buffer and NADPH-
regenerating system solution were pre-incubated at 37uC for 10
minutes. Reactions were initiated by the addition of the substrate
(verapamil) to the incubation mixture. The enzymatic process was
stopped by adding 500 mL of ice-cold acetonitrile. Different
incubation times were assessed: 15 minutes to 4 hours. Incubation
mixtures were centrifuged at 15,000 rpm for 10 minutes.
Supernatants (30 mL) were injected into the HPLC system and
the major metabolites of verapamil were monitored.
Inhibition studies. Different studies were conducted to
evaluate the potential contribution of CYP450s on the
metabolism of verapamil by human heart microsomes. Drug
inhibitors (metyrapone 100 mM, SKF525 100 mM, N-octylamine
100 mM or methimazole 200 mM) were added to incubation
mixtures containing human heart microsomes. Isozyme selective
inhibitors, sulfaphenazole (10 mM), ketoconazole (1 mM) and
quinidine (5 mM) were also evaluated. Briefly, the reaction
mixtures containing enzymatic sources, potassium buffer,
NADPH-regenerating system and inhibitor were warmed at 37uC
for 10 minutes prior to the addition of verapamil (400 mM).
Formation rates of verapamil metabolites were expressed as a
percentage of metabolites formed relative to the amounts of the
same metabolites formed in incubations containing no inhibitor.
A series of incubations was also performed with previously
inactivated human heart microsomes. The CYP450 proteins were
inactivated by heating microsomes at 60uC for 10 minutes.
Incubations were also conducted in the presence of nitrogen gas or
carbon monoxide gas in replacement of ambient air to inactivate
CYP450s. The extent of verapamil metabolism was measured as a
percentage of control activity.
NADPH-dependent enzymatic system. Verapamil
metabolite formation was studied in incubations performed with
or without a NADPH-regenerating system (incubations without
NADPH contained only vehicle, ie MgCL2).
Statistical analysis
Data are expressed as mean 6S.D. and when possible,
individual data are presented. Relative mRNA levels for various
isozymes were compared using a two-way ANOVA. The
comparison of CYP450 mRNA expression levels in failing hearts
with ischemic or non-ischemic disease was performed using an
unpaired t-test with Welch’s correction. An unpaired t-test with
Welch’s correction was also used assess and compare male and
female mRNA levels. mRNA levels for each isozyme in the left
and the right ventricles for each patient were compared using a
Wilcoxon signed rank test. This test was used when formation rate
of verapamil metabolites by left and right ventricles was studied
(paired samples of left and right ventricles from the same patients).
The metabolism of S-verapamil and R-verapamil within human
heart microsomes was also compared using the Wilcoxon signed
rank test. Differences were considered significant at p value ,0.05.
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